Literature DB >> 20040040

Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects.

J-S Hulot, G Wuerzner, C Bachelot-Loza, M Azizi, A Blanchard, S Peyrard, C Funck-Brentano, P Gaussem.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20040040     DOI： 10.1111/j.1538-7836.2009.03729.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  14 in total

1.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Authors:  Jessica L Mega; Tabassome Simon; Jean-Philippe Collet; Jeffrey L Anderson; Elliott M Antman; Kevin Bliden; Christopher P Cannon; Nicolas Danchin; Betti Giusti; Paul Gurbel; Benjamin D Horne; Jean-Sebastian Hulot; Adnan Kastrati; Gilles Montalescot; Franz-Josef Neumann; Lei Shen; Dirk Sibbing; P Gabriel Steg; Dietmar Trenk; Stephen D Wiviott; Marc S Sabatine
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

Review 2.  Antiplatelet drug interactions with proton pump inhibitors.

Authors:  Stuart A Scott; Aniwaa Owusu Obeng; Jean-Sébastien Hulot
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-11-09       Impact factor: 4.481

3.  Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.

Authors:  S A Scott; S Martis; I Peter; Y Kasai; R Kornreich; R J Desnick
Journal:  Pharmacogenomics J       Date:  2011-03-01       Impact factor: 3.550

Review 4.  Thienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance.

Authors:  Jean-Sébastien Hulot; Jean-Philippe Collet; Gilles Montalescot
Journal:  Curr Cardiol Rep       Date:  2011-10       Impact factor: 2.931

5.  Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.

Authors:  Nicolas Simon; Jonathan Finzi; Guillaume Cayla; Gilles Montalescot; Jean-Philippe Collet; Jean-Sébastien Hulot
Journal:  Eur J Clin Pharmacol       Date:  2015-06-14       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics and pharmacodynamics of clopidogrel.

Authors:  Xi-Ling Jiang; Snehal Samant; Lawrence J Lesko; Stephan Schmidt
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

Review 7.  Clopidogrel and PPI interaction: clinically relevant or not?

Authors:  Robert W Harrison; Kenneth W Mahaffey
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

8.  Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?

Authors:  Saoussen Chouchene; Rym Dabboubi; Haythem Raddaoui; Hela Abroug; Khaldoun Ben Hamda; Sondess Hadj Fredj; Fatma Abderrazak; Mayssa Gaaloul; Marwa Rezek; Fadoua Neffeti; Ilhem Hellara; Mouna Sassi; Linda Khefacha; Asma Sriha; Semir Nouira; Mohamed Fadhel Najjar; Faouzi Maatouk; Taieb Messaoud; Mohsen Hassine
Journal:  Eur J Clin Pharmacol       Date:  2018-08-03       Impact factor: 2.953

9.  Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.

Authors:  Renée M Ned Mmsc Phd
Journal:  PLoS Curr       Date:  2010-09-20

10.  Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.

Authors:  Jean-Philippe Collet; Jean-Sébastien Hulot; Jérémie Abtan; Ghalia Anzaha; Mathieu Kerneis; Johanne Silvain; Guillaume Cayla; Stephen A O'Connor; Olivier Barthélémy; Farzin Beygui; Sophie Galier; Delphine Brugier; Eric J Stanek; Scott L Charland; Vanessa Gallois; Gilles Montalescot
Journal:  Eur J Clin Pharmacol       Date:  2014-07-12       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.